Gesynta Pharma launches Phase 2 trial of promising Endometriosis drug
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The protections extend through at least 2035, with the potential for further extensions
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The agreement brings to market a method pioneered at CU Boulder that enables the reliable synthesis of long RNA strands
The first of four planned modules at the new plant is expected to come online by summer 2026
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
DiaMedica said it plans to launch the trial later in 2026
Subscribe To Our Newsletter & Stay Updated